• Back to Natural Antibody (Anti-Alpha-Galactosyl Antibody)

• Avrameas S. Natural autoantibodies: from 'horror autotoxicus' to 'gnothi seauton'. Immunol Today. 1991 May;12 (5):154-9
• Avrameas S, Dighiero G, Lymberi P, Guilbert B. Studies on natural antibodies and autoantibodies. Ann Immunol (Paris). 1983 Jul-Aug;134D (1):103-13
• Avrameas S, Guilbert B, Mahana W, Matsiota P, Ternynck T. Recognition of self and non-self constituents by polyspecific autoreceptors. Int Rev Immunol. 1988 Mar;3 (1-2):1-15
• Castronovo V, Colin C, Parent B, Foidart JM, Lambotte R, Mahieu P. Possible role of human natural anti-Gal antibodies in the natural antitumor defense system. J Natl Cancer Inst. 1989 Feb 1;81 (3):212-6
• Coutinho A, Kazatchkine MD, Avrameas S. Natural autoantibodies. Curr Opin Immunol. 1995 Dec;7 (6):812-8
• Dighiero G, Lymberi P, Guilbert B, Ternynck T, Avrameas S. Natural autoantibodies constitute a substantial part of normal circulating immunoglobulins. Ann N Y Acad Sci. 1986;475:135-45
• Galili U. Evolution and pathophysiology of the human natural anti-alpha-galactosyl IgG (anti-Gal) antibody. Springer Semin Immunopathol. 1993;15 (2-3):155-71
• Galili U, Anaraki F, Thall A, Hill-Black C, Radic M. One percent of human circulating B lymphocytes are capable of producing the natural anti-Gal antibody. Blood. 1993 Oct 15;82 (8):2485-93
• Galili U, Clark MR, Shohet SB, Buehler J, Macher BA. Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates. Proc Natl Acad Sci U S A. 1987 Mar;84 (5):1369-73
• Galili U, LaTemple DC. Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity. Immunol Today. 1997 Jun;18 (6):281-5
• Galili U, Macher BA, Buehler J, Shohet SB. Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1----3)-linked galactose residues. J Exp Med. 1985 Aug 1;162 (2):573-82
• Galili U, Mandrell RE, Hamadeh RM, Shohet SB, Griffiss JM. Interaction between human natural anti-alpha-galactosyl immunoglobulin G and bacteria of the human flora. Infect Immun. 1988 Jul;56 (7):1730-7
• Galili U, Swanson K. Gene sequences suggest inactivation of alpha-1,3-galactosyltransferase in catarrhines after the divergence of apes from monkeys. Proc Natl Acad Sci U S A. 1991 Aug 15;88 (16):7401-4
• Galili U, Wigglesworth K, Abdel-Motal UM. Intratumoral injection of alpha-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. J Immunol. 2007 Apr 1;178 (7):4676-87
• Good AH, Cooper DK, Malcolm AJ, Ippolito RM, Koren E, Neethling FA, Ye Y, Zuhdi N, Lamontagne LR. Identification of carbohydrate structures that bind human antiporcine antibodies: implications for discordant xenografting in humans. Transplant Proc. 1992 Apr;24 (2):559-62
• Hamadeh RM, Galili U, Zhou P, Griffiss JM. Anti-alpha-galactosyl immunoglobulin A (IgA), IgG, and IgM in human secretions. Clin Diagn Lab Immunol. 1995 Mar;2 (2):125-31
• Manches O, Plumas J, Lui G, Chaperot L, Molens JP, Sotto JJ, Bensa JC, Galili U. Anti-Gal-mediated targeting of human B lymphoma cells to antigen-presenting cells: a potential method for immunotherapy using autologous tumor cells. Haematologica. 2005 May;90 (5):625-34
• McMorrow IM, Comrack CA, Sachs DH, DerSimonian H. Heterogeneity of human anti-pig natural antibodies cross-reactive with the Gal(alpha1,3)Galactose epitope. Transplantation. 1997 Aug 15;64 (3):501-10
• Ochsenbein AF, Zinkernagel RM. Natural antibodies and complement link innate and acquired immunity. Immunol Today. 2000 Dec;21 (12):624-30
• Parker W, Bruno D, Holzknecht ZE, Platt JL. Characterization and affinity isolation of xenoreactive human natural antibodies. J Immunol. 1994 Oct 15;153 (8):3791-803
• STARZL TE, MARCHIORO TL, HOLMES JH, HERMANN G, BRITTAIN RS, STONINGTON OH, TALMAGE DW, WADDELL WR. RENAL HOMOGRAFTS IN PATIENTS WITH MAJOR DONOR-RECIPIENT BLOOD GROUP INCOMPATIBILITIES. Surgery. 1964 Feb;55:195-200
• Ternynck T, Avram